Methods for determining personalized treatment compositions for prostate cancer and breast cancer

A technology of compounds, therapies, applied in the field of identifying individualized therapeutic compositions for prostate cancer and breast cancer, capable of addressing slow progression of prostate or breast cancer, prostate cancer failure to address cancer specialists, etc.

Inactive Publication Date: 2015-09-02
CALDERA HEALTH
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, developments in diagnostic methods for both prostate and breast cancer have failed to address the issues facing cancer specialists
For example, current diagnostic techniques cannot determine whether each newly diagnosed prostate or breast cancer is a slowly growin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for determining personalized treatment compositions for prostate cancer and breast cancer
  • Methods for determining personalized treatment compositions for prostate cancer and breast cancer
  • Methods for determining personalized treatment compositions for prostate cancer and breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] As described below, when administered in combination Significant changes were observed in the peripheral blood immune cell subset analysis of prostate cancer patients compared with the peripheral blood immune cell subset analysis of healthy men before and after ketoconazole treatment. In all studies discussed below, peripheral blood immune subpopulation analysis was performed using blood from the same prostate cancer patients and the same healthy male donors.

[0086] A 66-year-old man with a 6-year history of previously diagnosed metastatic prostate cancer refractory to hormone ablation therapy stopped all treatment for three months. During the period, the patient's serum PSA level was 509 ng / ml. The patient was started on a daily injection of 0.5 mg and 400 mg of ketoconazole every eight hours for treatment. Blood samples were drawn before the start of treatment and immediately after three weeks of treatment. Leukocytes were collected from blood samples and anal...

Embodiment 2

[0095] The ability of activated immune cells to kill cancer cells was analyzed as follows.

[0096] Use a flow cytometer to simultaneously measure fluorescence at multiple different wavelengths, as well as light scattering in both directions at the rate of thousands of cells per second. To distinguish live cells from dead cells, various methods based on vital dyes are used. Examples of such dyes include: nucleic acid-binding fluorescent dyes such as ethidium bromide, ethidium iodide, and SYNTOX green, which are excluded by intact cells and accepted by dead cells; Molecules that persist while the plasma membrane remains intact, such as fluorescein acetate and carboxyfluorescein diacetate.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering a combination of at least two components selected from two different classes of compounds. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Patent Application 61 / 668,395, filed July 5, 2012, the entire contents of which are incorporated herein by reference. technical field [0003] The present invention relates to methods of determining optimal therapy comprising a combination of therapeutic compositions for an individual suffering from prostate or breast cancer. Background technique [0004] Prostate cancer is the most or second most common cancer diagnosed in men in many countries. Similarly, breast cancer is the most common, or second most common, cancer diagnosed in women in many countries. These two cancers share many commonalities in terms of epidemiology, genetics, biochemistry, and mechanistics. Morbidity, lifetime risk, dietary factors (especially high-fat and low-fiber diets), mortality, ethnic trends, and country of residence are common epidemiological features. Furthermore, steroid hormo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/574C12N5/0783C12N5/09A61K38/16
CPCG01N2800/52A61K38/193G01N33/57434A61K31/496G01N33/57415G01N33/5047A61K45/06A61K31/497A61P35/00A61K2300/00
Inventor 詹姆斯·道格拉斯·沃特森理查德·卢埃林·西德尼·福斯特
Owner CALDERA HEALTH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap